Truscreen Group

Truscreen Group Current Assets

The Current Assets of Truscreen Group (TRU.NZ) as of Oct 31, 2026 is 1.54 M NZD. In the previous year, Current Assets was 4.03 M NZD — a change of -61.75% (lower).

Current Assets

1.54 MNZD

YoY

-61.75%

Last updated:

Current Assets of Truscreen Group is 2025 1.54 M NZD. Current Assets of Truscreen Group was 2024 4.03 M NZD. It decreases by -61.75% lower compared to the previous year.

The Truscreen Group Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
3.21 M NZD
Jan 1, 2019
3.90 M NZD
Jan 1, 2020
2.55 M NZD
Jan 1, 2021
6.70 M NZD
Jan 1, 2022
4.39 M NZD
Jan 1, 2023
3.47 M NZD
Jan 1, 2024
4.03 M NZD
Jan 1, 2025
1.54 M NZD
The Truscreen Group Current Assets history
YEARCurrent AssetsYoY
1.54 MNZD-61.75%
4.03 MNZD+16.14%
3.47 MNZD-20.90%
4.39 MNZD-34.49%
6.70 MNZD+162.80%
2.55 MNZD-34.74%
3.90 MNZD+21.47%
3.21 MNZD-39.29%
5.29 MNZD+27.60%
4.15 MNZD+7.78%
3.85 MNZD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Truscreen Group Stock analysis

What does Truscreen Group do? TruScreen Group Ltd develops and sells cancer detection devices and systems, focusing on cervical cancer screening. The company's AI-enabled device uses opto-electrical technology to detect precancerous and cancerous cervical changes in real-time through optical and electrical measurements of cervical tissue. The TruScreen device includes a Disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC), working together to resolve issues with cytology such as failed samples, poor patient follow-up, and patient discomfort. The company also addresses challenges with HPV testing by providing an alternative solution that avoids the need for laboratory infrastructure. The primary buyers of TruScreen's products are healthcare providers and clinics specializing in women's health, particularly those seeking efficient, real-time cervical screening solutions. The technology targets segments where traditional cytology and HPV testing face limitations, such as in resource-constrained settings or where patient adherence to follow-up is low. By offering a device that eliminates the need for supporting laboratory infrastructure, TruScreen appeals to providers looking to streamline cervical cancer screening processes. TruScreen's products are designed to replace or complement existing cervical screening methods, directly addressing the shortcomings of cytology and HPV testing. The company's focus on real-time detection and ease of use positions it as a solution for healthcare systems aiming to improve early cancer detection rates while reducing patient discomfort and logistical challenges associated with current screening practices. Truscreen Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Truscreen Group stock

Current Assets of Truscreen Group is 1.54 M NZD in 2025.

Current Assets of Truscreen Group changed from 4.03 M NZD to 1.54 M NZD, representing a -61.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Truscreen Group since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's NZD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Truscreen Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Truscreen Group

All Key Metrics — Truscreen Group